



## PURPOSE

The [Initiative for Multipurpose Prevention Technologies \(IMPT\)](#) is developing tools to help support and guide MPT product development and investment decisions. These include an MPT product development and gap analysis exercise, which is updated annually. This report provides a summary of the MPT Product Prioritization and Gap Analysis for 2014, as led by the IMPT's Scientific Agenda Working Group (SAWG). The survey is designed to achieve new recommendations and updates to the 2013 IMPT product prioritization findings. Specifically, stakeholder perspectives were solicited on MPT product development priorities and gaps. Data are both quantitative and qualitative.

Survey findings inform IMPT efforts to support strategic focus on MPT priority product development strategies among funders and product development organizations. Similarly, the effort supports coordinated focus on gap resolution for the MPT field. The product prioritization survey also provides a basis for target product profile (TPP) development, and is complemented with efforts to understand and address social-behavioral and commercialization issues relevant to achieving high impact MPT products.

## METHODOLOGY

In February 2014, the survey was initially distributed to members of the SAWG and SACC (n=18). By early April, 10 surveys were returned. To receive input from a wider array of experts, the survey was distributed in April to 109 experts, including members of the IMPT regional partners in China, Kenya, India, South Africa, and Zimbabwe, as well as in Europe and the US. Due to a limited response rate, the survey was re-distributed in July and partners were encouraged to complete the survey during regional working group calls. At the end of the data collection process in September 2014, a total of 21 surveys were completed.



## RESULTS

The summary below reports findings from the MPT Product Prioritization and Gap Analysis for 2014. These findings should be interpreted with the respondent sample in mind; the primary perspective represented being from United States MPT R&D stakeholders and funders. There was a consensus that **there have there been no new developments in the field that justify changing the priority indications, drugs, or dosage-forms** identified in 2013 by the IMPT product prioritization effort.

### Priority MPT Indications, Drugs, & Dosage Forms

- ❖ Indications
  - Prevention of **HIV, unintended pregnancy** and other **sexually transmitted infections (STIs)** are prioritized as the most relevant MPT indications.
  - **Viral STIs** prioritized over other STIs
  - **HSV** prioritized over HPV
- ❖ Active Pharmaceutical Ingredients (APIs)
  - **ARV** and **hormonal contraception (HC)** prioritized
  - STI options lacking
- ❖ Dosage-Forms
  - Confirmed need for suite of products
  - **Intravaginal rings (IVRs)** and **long-acting injectables (LAIs)** prioritized over on-demand MPT options
  - For on-demand options, **vaginal films and tablets** were favored over gels

### Other Priority Considerations & Gaps

- ❖ APIs
  - In addition to HC, **non-HC options** for contraception are needed
  - **Surfactants, rProteins, polyAs** seen as more challenging (low priorities)
  - Advantages with **small molecules** and **approved drugs**
  - **ARV options not used for treatment** preferred
- ❖ Dosage-Forms
  - Consensus that adequate **acceptability data for each dosage-form and product is lacking**,
  - Appropriate **commercialization feasibility assessments** needed for prioritized products
  - Strong acceptance of **co-administration as an MPT concept** (e.g. LAIs)
- ❖ **Inadequate data/knowledge on the use of HC and ARV** in on-demand products

Given the consistency in results between the 2014 and 2013 product prioritization exercises, the IMPT is considering alternatives to an annual prioritization survey focused on product issues and gaps. As the number and complexity of issues confronting MPTs expands with the overall progress of the field, focus on more specialized areas of relevance to the wider field may be more valuable. Thus, the IMPT is evaluating a strategy that surveys MPT priority issues beyond those limited to the product pipeline that will continue to inform a coordinated and complementary approach to achieving successful development and delivery of MPT products to at-risk women around the world.

*Suggested Citation:* CAMI Health. Technical Brief. MPT Product Prioritization and Gap Analysis: 2014 Summary. January 2015



**The Initiative for Multipurpose Prevention Technologies (IMPT)** is an international collaboration of diverse stakeholders working across the sexual and reproductive health (SRH) fields committed to safely and swiftly bringing new MPTs to market. By working together, we share vital findings, avoid duplicating efforts and can efficiently advance the development of MPTs to save lives.



**CAMI Health** works to promote innovative prevention strategies that enhance women's SRH in the US and across the globe. As Secretariat of the IMPT, we operate as a neutral, product-agnostic coalition. Our work is done through collaboration, convenings, advocacy and research.